CLEC12A and acute myeloid leukemia: A trispecific killer cell engager (TriKE) targeting CLL-1 on leukemic cells and CD16/IL15 on NK cells increased NK cell proliferation and degranulation in leukemic cells, resulting in death in approximately 15% of the AML cells in vitro, which was comparable to that of CD33-targeted TriKE [105].